Aradigm Overview
- Year Founded
-
1991
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Grant
- Financing Rounds
-
14
Aradigm General Information
Description
Aradigm Corp is a United States based specialty pharmaceutical company. It develops and commercializes drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. The company has respiratory inhalation products in preclinical and clinical development for the treatment of cystic fibrosis, bronchiectasis, biodefense, and tobacco smoking cessation. It derives revenue from the grants, collaboration agreements, and feasibility studies.
Contact Information
Website
www.aradigm.comCorporate Office
- 3929 Point Eden Way
- Hayward, CA 94545
- United States
Corporate Office
- 3929 Point Eden Way
- Hayward, CA 94545
- United States
Aradigm Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aradigm Comparisons
Industry
Financing
Details
Aradigm Competitors (47)
One of Aradigm’s 47 competitors is United Biomedical, a Venture Capital-Backed company based in Dallas, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| United Biomedical | Venture Capital-Backed | Dallas, TX | ||||
| Indivior | Corporate Backed or Acquired | North Chesterfield, VA | ||||
| CEL-SCI | Corporation | Vienna, VA | ||||
| Ampio Pharmaceuticals | Corporation | Englewood, CO | ||||
| Actinium Pharmaceuticals | Formerly VC-backed | New York, NY |
Aradigm Patents
Aradigm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020167429-A1 | An antibiotic formulation for use in treating bronchiectasis | Inactive | 11-Feb-2019 | ||
| WO-2018186998-A1 | Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm | Inactive | 05-Apr-2017 | ||
| WO-2017123315-A2 | Nanocrystals formed in a microenvironment | Inactive | 12-Jan-2016 | ||
| WO-2017123315-A3 | Nanocrystals formed in a microenvironment | Inactive | 12-Jan-2016 | ||
| AU-2015244275-A1 | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria | Active | 08-Apr-2014 | A61K31/496 |
Aradigm Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aradigm Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aradigm FAQs
-
When was Aradigm founded?
Aradigm was founded in 1991.
-
Where is Aradigm headquartered?
Aradigm is headquartered in Hayward, CA.
-
What is the size of Aradigm?
Aradigm has 23 total employees.
-
What industry is Aradigm in?
Aradigm’s primary industry is Drug Discovery.
-
Is Aradigm a private or public company?
Aradigm is a Private company.
-
What is Aradigm’s current revenue?
The current revenue for Aradigm is .
-
How much funding has Aradigm raised over time?
Aradigm has raised $178M.
-
Who are Aradigm’s investors?
Grifols and First Eagle Investments have invested in Aradigm.
-
Who are Aradigm’s competitors?
United Biomedical, Indivior, CEL-SCI, Ampio Pharmaceuticals, and Actinium Pharmaceuticals are some of the 47 competitors of Aradigm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
